Skip to content

Study · Not a test of the peptide alone · 2009

1 result

Physicochemical and pharmacological characterization of novel vasoactive intestinal peptide derivatives with improved stability.

Onoue S, Misaka S, Ohmori Y, Sato H, Mizumoto T, Hirose M, Iwasa S, Yajima T, Yamada S

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V28 May 2009Cited by 9 (Europe PMC)

PMID19481602 (opens in a new tab)DOI10.1016/j.ejpb.2009.05.013 (opens in a new tab)PepBankPUB-19481602
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In rat PC12 cells, novel stabilised VIP derivatives caused more potent neurite outgrowth than native VIP and IK312532; native VIP was the comparator.

    In plain wordsIn cells, the new modified VIP-based compounds grew nerve extensions more strongly than natural VIP did.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableNeurite outgrowth of novel VIP derivatives versus VIP
    Study

    ratn: not reported in source

    PC12 pheochromocytoma cells
    Comparator
    VIP and IK312532
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Novel derivatives also exhibited more potent neurite outgrowth in rat pheochromocytoma PC12 cells when compared to VIP and IK312532, possibly due to improved stability.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.